iShares US Pharmaceuticals ETF
92 hedge funds and large institutions have $276M invested in iShares US Pharmaceuticals ETF in 2016 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 27 increasing their positions, 27 reducing their positions, and 10 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
100% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 10
76% more capital invested
Capital invested by funds: $157M → $276M (+$119M)
42.05% more ownership
Funds ownership: 78.78% → 120.84% (+42%)
10% more funds holding
Funds holding: 84 → 92 (+8)
0% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 27
63% less call options, than puts
Call options by funds: $537K | Put options by funds: $1.47M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CI
Clal Insurance
Tel-Aviv,
Israel
|
+$64.8M |
| 2 |
PAG
Pinnacle Advisory Group
Columbia,
Maryland
|
+$18.8M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$15.7M |
| 4 |
Morgan Stanley
New York
|
+$9.55M |
| 5 |
RTS
Round Table Services
Westfield,
New Jersey
|
+$6.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
-$4.48M |
| 2 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$4.27M |
| 3 |
ST
Spinnaker Trust
Portland,
Maine
|
-$1.89M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.71M |
| 5 |
Brown Advisory
Baltimore,
Maryland
|
-$1.09M |
IHE Hedge Fund Activity: Q4 2016 in Review
92 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in iShares US Pharmaceuticals ETF (IHE) for Q4 2016, worth a combined $276M — up 76% from $157M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new IHE positions and 10 closed out — a net gain of 10 holders — while 27 added to existing stakes and 27 trimmed.
The largest buyer was Clal Insurance, opening a new position worth an estimated $64.8M. The largest seller was Jane Street, exiting entirely with an estimated $4.48M sold.
- 92 institutional investors held iShares US Pharmaceuticals ETF (IHE) as of Q4 2016, up from 84 in Q3 2016.
- Funds reported $276M of iShares US Pharmaceuticals ETF stock for Q4 2016, up 76% quarter-over-quarter.
- 20 funds opened new iShares US Pharmaceuticals ETF positions in Q4 2016 and 10 closed out, a net change of +10 holders.
- The largest iShares US Pharmaceuticals ETF buyer in Q4 2016 was Clal Insurance, an estimated $64.8M added.
- The largest iShares US Pharmaceuticals ETF seller in Q4 2016 was Jane Street, an estimated $4.48M sold.
Based on aggregated 13F filings for Q4 2016.